We read with interest the letter by Chen et al. We address the main points raised by Chen et al. and provide a series of evaluations supporting the view that the findings presented in the original article should be interpreted with caution given the potential confounding factors and limitations in patient selection.
Comment on "Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata" / L. Valtellini, A. Sechi, A.V. Marzano, S.M. Ferrucci. - In: CLINICAL AND EXPERIMENTAL DERMATOLOGY. - ISSN 0307-6938. - 50:7(2025), pp. 1416-1417. [10.1093/ced/llaf085]
Comment on "Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata"
L. ValtelliniPrimo
;A.V. Marzano;
2025
Abstract
We read with interest the letter by Chen et al. We address the main points raised by Chen et al. and provide a series of evaluations supporting the view that the findings presented in the original article should be interpreted with caution given the potential confounding factors and limitations in patient selection.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
llaf085.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Licenza:
Nessuna licenza
Dimensione
632.33 kB
Formato
Adobe PDF
|
632.33 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
